Renal function in patients with non-dialysis chronic kidney disease receiving intravenous ferric carboxymaltose: an analysis of the randomized FIND-CKD trial

نویسندگان

  • Iain C. Macdougall
  • Andreas H. Bock
  • Fernando Carrera
  • Kai-Uwe Eckardt
  • Carlo Gaillard
  • David Van Wyck
  • Yvonne Meier
  • Sylvain Larroque
  • Simon D. Roger
  • Simon D. Roger
  • Alastair Gilles
  • Randall Faull
  • Nigel D. Toussaint
  • Lawrence McMahon
  • Michael Suranyi
  • David Mudge
  • Brian Hutchison
  • Ashley Irish
  • Peter Kerr
  • Hemant Kulkarni
  • Grahame Elder
  • Margaret Jardine
  • Karl Lhotta
  • Gert Mayer
  • Raymond Vanholder
  • Bart Dirk Maes
  • Pieter Evenepoel
  • Frédéric Debelle
  • Michel Jadoul
  • Max Dratwa
  • Igor Macel
  • Milan Dunaj
  • Milan Kvapil
  • Petr Bucek
  • Jitka Rehorova
  • Ales Hruby
  • Václava Honová
  • Lada Malanova
  • Martin Lucak
  • Dalibor Lecian
  • Martin Jirovec
  • Jiri Vlasak
  • Ivan Rychlik
  • Stanislav Surel
  • Anne-Lise Kamper
  • Ove Ostergaard
  • Gudrun K. Steffensen
  • Leila Chenine
  • Gabrial Choukroun
  • Philippe Zaoui
  • Christoph Wanner
  • Wolfgang Backs
  • Uwe Kraatz
  • Frank Dellanna
  • Klaus Busch
  • Tobias Marsen
  • Wolfgang Seeger
  • Rainer Woitas
  • Nicholas Obermueller
  • Thomas Haak
  • Stephan Lueders
  • Frank Pistrosch
  • Eckhard Mueller
  • Peter R. Mertens
  • Werner Sutermer
  • Scott-Oliver Grebe
  • Syrus Hafezi-Rachti
  • Silke Roeser
  • Dimitrios Tsakiris
  • Dimitrios Memmos
  • Demetrios Vlachakos
  • Vassilis Vargemezis
  • Ioannis Stefanidis
  • Christos Syrganis
  • Polichronis Alivanis
  • Ioannis Papadakis
  • Nickolaos Papagalanis
  • Aimilios Andrikos
  • Dimitrios Goumenos
  • Kostas Siamopoulos
  • Charikelia Gouva
  • Gabriel Papadakis
  • Ioannis Boletis
  • Myrsini Tsimnadi-Spanoudaki
  • Dimitrios Stamatiades
  • Kyriaki Stamatelou
  • Spyridon Moutafis
  • Francesco Locatelli
  • Antonio Santoro
  • Francesco Quarello
  • Giuseppe Remuzzi
  • Salvatore Coppola
  • Rosella Ferraro Mortellaro
  • Andrea Icardi
  • Giacomo Colussi
  • Franco Della Grotta
  • Luigi Lombardi
  • Maurizio Gallieni
  • Giuseppe Villa
  • Giuseppe Grandaliano
  • Carlo Gaillard
  • Sebastiaan Huisman
  • Jos Barendregt
  • Peter J. H. Smak Gregoor
  • Cecilia Oien
  • Boleslaw Rutkowski
  • Robert Malecki
  • Michal Nowicki
  • Przemyslaw Rutkowski
  • Kryzsztof Marczewski
  • Michal Mysliwiec
  • Antoni Sydor
  • Jacek Rysz
  • Andrzej Rydzewski
  • Marian Klinger
  • Rafal Wnuk
  • Piotr Kozminski
  • Anna Nocon
  • Kazimierz Ciechanowski
  • Pedro Correia
  • Fernando Neves
  • José Barata
  • Gabriel Mircescu
  • Mihai Voiculescu
  • Gheorghe Gluhovschi
  • Eugen Mota
  • Angel Luís Martín De Francisco
  • Alberto Torre
  • Alba Herreros
  • José Luño
  • E Gruss
  • Judith Martins
  • Marti Vallés
  • Julio Pascual
  • Peter Bárány
  • Andreas H. Bock
  • Patrice M. Ambuehl
  • Sehsuvar Erturk
  • Mustafa Arici
  • Saime Paydas
  • Zeki Soypacaci
  • Taner Camsari
  • Sedat Ustundag
  • Iain C. Macdougall
  • Mark E. Thomas
  • Richard J. D’Souza
  • Jo E. Taylor
  • Nicholas R. Pritchard
  • Robin Jeffery
  • Stephen G. Riley
  • Deepak Bhatnagar
  • Sunil Bhandari
  • David Reaich
  • Paul E. Stevens
  • Mohsen El Kossi
  • Simon Roe
  • Brian Camilleri
  • Aimun Ahmed
  • Arif Khwaja
  • Barbara Thompson
  • Debasish Banerjee
  • Johann Nicholas
  • Alistair Hutchison
  • Richard Borrows
چکیده

BACKGROUND Preclinical studies demonstrate renal proximal tubular injury after administration of some intravenous iron preparations but clinical data on renal effects of intravenous iron are sparse. METHODS FIND-CKD was a 56-week, randomized, open-label, multicenter study in which patients with non-dialysis dependent chronic kidney disease (ND-CKD), anemia and iron deficiency without erythropoiesis-stimulating agent therapy received intravenous ferric carboxymaltose (FCM), targeting either higher (400-600 μg/L) or lower (100-200 μg/L) ferritin values, or oral iron. RESULTS Mean (SD) eGFR at baseline was 34.9 (11.3), 32.8 (10.8) and 34.2 (12.3) mL/min/1.73 m2 in the high ferritin FCM (n = 97), low ferritin FCM (n = 89) and oral iron (n = 167) groups, respectively. Corresponding values at month 12 were 35.6 (13.8), 32.1 (12.7) and 33.4 (14.5) mL/min/1.73 m2. The pre-specified endpoint of mean (SE) change in eGFR from baseline to month 12 was +0.7 (0.9) mL/min/1.73 m2 with high ferritin FCM (p = 0.15 versus oral iron), -0.9 (0.9) mL/min/1.73 m2 with low ferritin FCM (p = 0.99 versus oral iron) and -0.9 (0.7) mL/min/1.73 m2 with oral iron. No significant association was detected between quartiles of FCM dose, change in ferritin or change in TSAT versus change in eGFR. Dialysis initiation was similar between groups. Renal adverse events were rare, with no indication of between-group differences. CONCLUSION Intravenous FCM at doses that maintained ferritin levels of 100-200 μg/L or 400-600 μg/L did not negatively impact renal function (eGFR) in patients with ND-CKD over 12 months versus oral iron, and eGFR remained stable. These findings show no evidence of renal toxicity following intravenous FCM over a 1-year period. TRIAL REGISTRATIONS ClinicalTrials.gov NCT00994318 (first registration 12 October 2009).

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia

BACKGROUND The optimal iron therapy regimen in patients with non-dialysis-dependent chronic kidney disease (CKD) is unknown. METHODS Ferinject® assessment in patients with Iron deficiency anaemia and Non-Dialysis-dependent Chronic Kidney Disease (FIND-CKD) was a 56-week, open-label, multicentre, prospective and randomized study of 626 patients with non-dialysis-dependent CKD, anaemia and iron...

متن کامل

Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: a randomized, active-controlled, multi-center study.

BACKGROUND Currently available intravenous (IV) iron agents vary in indication, dosing regimens and safety profiles. Ferric carboxymaltose (FCM) is a stable, non-dextran-containing iron formulation developed for rapid IV administration in high doses with controlled delivery of iron into target tissues. The objective of the present study was to evaluate the safety of FCM compared with standard m...

متن کامل

The FIND-CKD study—a randomized controlled trial of intravenous iron versus oral iron in non-dialysis chronic kidney disease patients: background and rationale

BACKGROUND Rigorous data are sparse concerning the optimal route of administration and dosing strategy for iron therapy with or without concomitant erythropoiesis-stimulating agent (ESA) therapy for the management of iron deficiency anaemia in patients with non-dialysis dependent chronic kidney disease (ND-CKD). METHODS FIND-CKD was a 56-week, open-label, multicentre, prospective, randomized ...

متن کامل

Switching Patients with Non-Dialysis Chronic Kidney Disease from Oral Iron to Intravenous Ferric Carboxymaltose: Effects on Erythropoiesis-Stimulating Agent Requirements, Costs, Hemoglobin and Iron Status

BACKGROUND Patients with non-dialysis-dependent chronic kidney disease (ND-CKD) often receive an erythropoiesis-stimulating agent (ESA) and oral iron treatment. This study evaluated whether a switch from oral iron to intravenous ferric carboxymaltose can reduce ESA requirements and improve iron status and hemoglobin in patients with ND-CKD. METHODS This prospective, single arm and single-cent...

متن کامل

Randomized evaluation of efficacy and safety of ferric carboxymaltose in patients with iron deficiency anaemia and impaired renal function (REPAIR-IDA): rationale and study design.

BACKGROUND Patients with iron deficiency anaemia (IDA) in the setting of non-dialysis-dependent chronic kidney disease (NDD-CKD) may benefit from treatment with intravenous (IV) iron. Ferric carboxymaltose (FCM) is a novel IV iron formulation designed to permit larger infusions compared to currently available IV standards such as Venofer(R) (iron sucrose). METHODS The primary objective of REP...

متن کامل

Hepcidin Response to Iron Therapy in Patients with Non-Dialysis Dependent CKD: An Analysis of the FIND-CKD Trial

Hepcidin is the key regulator of iron homeostasis but data are limited regarding its temporal response to iron therapy, and response to intravenous versus oral iron. In the 56-week, open-label, multicenter, prospective, randomized FIND-CKD study, 626 anemic patients with non-dialysis dependent chronic kidney disease (ND-CKD) and iron deficiency not receiving an erythropoiesis stimulating agent ...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره 18  شماره 

صفحات  -

تاریخ انتشار 2017